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The Polish Hound (ogar polski) is a small, old breed of hunting dogs.The breed was recognized by the Fédération Cynologique 
Internationale (FCI) in 1966.A three–year–old Polish Hound male, was admitted to the Clinic of Internal Diseases of Companion 
Animals of Life Science University in Lublin because of signs of haemorhagic diathesis. There was no preceding history of trauma. 
General clinical examination was unremarkable. On initial diagnostic testing prothrombin time (PT)of the patient was prolonged 
nearly by three times. To characterize the dog’s coagulopathy further, samples were collected for coagulation screening tests, mixing 
studies and factor analyses. Investigations revealed factor VII activity below 2%.Unfortunately we had been unable to determine 
whether the disorder is inherited or is the result of a spontaneous mutation. It is very likely that the nature of described deficit is 
inherited. Canine hereditary FVII deficiency was first described in 1962 as an incidental finding in Beagles. Later, the defect was 
identified in another breeds, such as: English Bulldogs, Alaskan Malamutes, Miniature Schnauzers, Boxers, Scottish Deerhounds, 
Alaskan Klee Kai Dog and mixed–breed dogs. In 2005 a molecular characterization of FVII deficiency in Beagles was described. 
Unfortunately we had been unable to determine whether the disorder is inherited or is the result of a spontaneous mutation. To our 
knowledge this case is the first to report of isolated factor VII deficiency in Polish Hound. 
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hereditary deficiency, genetic diseases. 
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Introduction  
 
The Polish Hound (ogar polski) is an old, traditional 
breed of hunting dogs. This breed is considered to have 
descended from the Kostroma Hound or was developed 
through crossbreeding of Bloodhounds imported to 
Poland in the Middle Ages, with local dogs. World War II 
resulted in the dramatic decline of the Polish Hounds' 
population. The postwar restoration of Polish Hound were 
undertaken by Piotr Karwiak. The common dog we see 
today typically goes back to just two dogs and two bitches 
brought over to Poland in 1959 from Lithuania territory. 
The breed was recognized by the Fédération Cynologique 
Internationale (FCI) in 1966.The current population of 
Polish Hounds is estimated at 1000 animals (Głażewska, 
2008; Głażewska and Prusak, 2012; Książek et al., 2014). 
Unfortunately the low number of the founders may result 
in the decreasing of genetic variability and in 
consequence declining health condition of the breed 
(Frankham, 1996). This can be seen as, for instance, 
smaller size of litter, increased neonatal death or high 
frequency of genetic disease. A classic example of such 
problems is population of Dobermans where 
approximately 30% of dogs are affected with von 
Willebrand's disease, 50% are carriers of the vWD gene 
and only 20% of Dobermans are completely clear of the 
disease gene (Mostoskey et al., 2000). What is the 
incidence of genetic diseases in Polish Hounds? It is 
difficult to assess the incidence of such diseases in this 
breed for the lack of the database and due to the 
unwillingness to provide information by breeders and dog 
owners. So far only the occurrence of entropion condition 
in Polish Hounds has been described by Łuczak and 
Balicki (Książek et al., 2014).  
Case study. A three–year–old Polish Hound male, 
registered in the Introductory Book (father of this dog 
registered in the Polish Pedigree Book and mother in the 
Introductory Book) was admitted on 16th May 2016 to 
the Clinic of Internal Diseases of Companion Animals of 
Life Science University in Lublin because of hyphaema 
formation in anterior chamber of the eye. The patient was 
reffered from the surgical ward,where had been treated 
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earlier due to suspicion of uveitis. Topical ophthalmic 
drugs and orally non–steroidal anti–inflammatories were 
administered over two weeks without improvement. 
There was no preceding history of trauma. General 
clinical examination was unremarkable. Physical exam of 
the skin and mucous membranes revealed no hemorrhages 
or other hemorrhagic symptoms however excessive 
bleeding was noted at phlebotomy sites. Abdominal 
ultrasound did not reveal any significant abnormalities. 
To characterize the dog’s status further, blood samples 
were collected for CBC, biochemistry andcoagulation 
screening tests.The CBC parametersand basic serum 
biochemistry profile (urea 37.12 mg/dl, glucose 98.3 
mg/dl, GPT 23 U/l)of the patient were within normal 
ranges. On initial diagnostic testing platelet count and 
activated partial thromboplastin time (APTT) both were 
within normal limits. Platelet function as measured by the 
PFA–200 was correct.  
Only prothrombin time (PT) was prolonged nearly by 
three times. Ingestion of an anticoagulant was suspected, 
although the dog–owner denied accidental ingestion of rat 
poison by the dog. 
 
Tab. 1  
Initial CBC and coagulation panel of the patient (the day 0). 
Parameter units Result Normal range Parameter units Result Normal range 
WBC 109/l 6.8 6.0 – 12.0 PT s 34.2 8.0 – 12.0 
RBC 1012/l 6.19 5.50 – 8.50 Wsk. PT % 37  
HCT % 44.0 44.0 – 57.0 INR – 2.86 0.8 – 1.2 
HGB g/dl 16.1 15.0 – 20.0 APTT s 13.1 12.0 – 25.0 
MCV fl 71 60 – 77 APTT Ratio – 0.37 – 
MCH pg 25.9 17.0 – 26.0 Fibrinogen mg/dl 300 150 – 350 
MCHC g/dl 36.5 31.0 – 38.0     
RDW% % 15.6 14.0 – 17.0 COL/ADP s 53 50.0 – 80.0 
PLT 109/l 280 200 – 460 COL/EPI s 110 80.0 – 120.0 
 
To correct presumed deficiency of the vitamin K, the 
dog was treated with orally vitamin K (Vitakon 1 mg/kg 
PO SID) for one week. At that time the dog was clinically 
normal. The hyphema resolved completely but 
administration of vitamin K had no effect on PT. It was 
even longer (41.5 s; INR 3.52) than at presentation. In 
such condition, hereditary coagulation factors deficiency 
or presence of coagulation factors inhibitors were 
suspected as the cause of coagulopathy. To characterize 
the dog’s coagulopathy further, samples were collected 
for coagulation screening tests, mixing studies and factor 
analyses. 
Coagulation Assays. Coagulation assays were 
performed on fresh citrate plasma samples with an APTT 
reagent,and a PT reagent (Bio–Ksel, Toruń, Poland), in an 
automatic coagulation analyzer, Bioksel6000 (Bio–Ksel, 
Toruń, Poland). All assays utilized human lyophilised 
plasma (Bio–Ksel, Toruń, Poland) for the preparation of 
the calibration and QC. All the required materials are 
commercially available. 
Mixing studies. Mixing studies were performed to 
detect a potential circulating inhibitor. 
Immediate mixing studies. Pooled dog's normal 
platelet poor plasma (NPP prepared from 20 healthy dogs) 
and patient plasma were mixed at a ratio of 1:1. 
Immediately after preparation, the PT of the1:1mix was 
tested in the coagulation analyzer and clotting time was 
recorded.  
Incubated mixing studies. Normal citrated (NPP) and 
test plasma were mixed in a1:1 ratio and after 2h at 37 °C 
incubation period the PT of the mix was determined in an 
automated coagulation analyzer. 
Assays for coagulation factors V and VII. 
Coagulation factor V and VII activities were measured by 
one stage PT–derived assay in which the ability of the 
patient’s plasma to normalize the prolonged clotting time 
of specific factor–deficient human plasma was determined 
(Zondag et al., 1985; Friederich, et al., 2003). The results 
were expressed as a percentage of factors activity in 
standard human plasma which had an assigned value of 
100%. 
 
Results 
 
Table 2 shows the results obtained for different 
coagulation tests in patient's blood samples collected at 
the day +8 after admission. Activated Partial 
Thromboplastin Time (APTT) and fibrinogen levels were 
normal. The patients had only isolated PT 
prolongation.Both types of mixing studies corrected the 
initially prolonged PT to normal range. Further 
investigations revealed factor VII activity below 2%. 
Factor V assay was normal. After 34 days factor VII level 
was higher (4.32%). 
Tab. 2  
Results of coagulation assays (the day +8). 
Parameter units NPP Patient plasma Immediate mixing studies Incubated mixing studies Normal range
PT [s] 9.1 43.5 13.2 12.3 8.0 – 12.0 
APTT [s] 12.8 13.5 – – 12.0 – 25.0 
Factor V % 482 468 – – 400 – 500 
Factor VII % 350 <2% – – ~ 370 
Fibrinogen mg/dl 212 260 – – 150 – 350 
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Discussion 
 
Factor VII is a vitamin K–dependent serine protease 
glycoprotein with a pivotal role inextrinsic pathway of 
coagulation. It is, as most of clotting factors, synthesized 
in the liverand secreted as a single–chain glycoprotein of 
48 kD. The gene coding factor VII is located in humans 
on band 13at position q34 (Mariani et al., 2005; Callan et 
al., 2006). The first case of isolated factor VII deficiency 
in a child was described by Alexander in 1951 (Alexander 
et al., 1951). Inherited factor VII (FVII) deficiency is a 
rare autosomal recessive hemorrhagic disorder prevalence 
of which it is estimated to be 1 case per 500,000 persons 
in the general population (Friederich et al., 2003; Mariani 
et al., 2005). So far more than 100 mutations, have been 
identified in the human factor VII gene (Mariani et al., 
2005). Inherited factor VII deficiency can be classified as 
type 1 (decreased biosynthesis) or type 2 (dysfunctional 
pattern) (Tuddenham et al., 1995). It can result in mild to 
moderate blood clotting disorder. Clinical bleeding can 
widely vary and does not always correlate with the level 
of factor VII coagulant activity measured in plasma. 
Canine hereditary FVII deficiency was first described 
in 1962 as an incidental finding in Beagles (Aljamali et 
al., 2005). Later, the defect was identified in another 
breeds, such as: English Bulldogs, Alaskan Malamutes, 
Miniature Schnauzers, Boxers, Scottish Deerhounds, 
Alaskan Klee Kai Dogand mixed–breed dogs (Callan et 
al., 2006; Kaae et al., 2007). Until recently factor VII 
deficiency could only be diagnosed by measuring the 
level of factor VII in the blood. In 2005, Aljamaliand 
coworkers (Aljamali et al., 2005). described a molecular 
characterization of FVII deficiency in Beagles. It was a 
mutation located in exon 5 resulting in the substitution of 
glycine 96 (GGA) to glutamic acid (GAA) in the second 
epidermal growth factor–like domain (Aljamali et al., 
2005). Further researches have shown that the same 
mutation is responsible for deficiency of FVII in another 
dog breeds (Kaae et al., 2007). In affected dogs the 
related clinical signs are typically mild. Excessive 
bleeding only occurs after a severe trauma or surgery.  
In the case described above bleeding signs were rather 
mild. Primary haemostasis and intrinsic pathway of 
coagulation were found to be normal. The investigations 
revealed only prolonged prothrombin time (PT). The PT 
may be prolonged due to deficiency of one or more 
clotting factors or due to the presence of an inhibitor that 
interferes with the normal function of a coagulation 
factor. Since anticoagulant rodenticide poisoning remains 
a common health problem among pets in Poland therefore 
a presumptive diagnosis of toxicosis was made. Mixing 
studies results allow to exclude the presence of 
anticoagulant in the circulation as the cause of the 
coagulopathy. Ultimate diagnosis was made based upon 
persistent low factor VII activity. Unfortunately we had 
been unable to determine whether the disorder is inherited 
or is the result of a spontaneous mutation. It is very likely 
that the nature of described deficit is inherited because 
since the 1970’s, to improve basic anatomical measures 
and the declining health condition of the breed, dogs of 
unknown origin have been used in breeding (Książek et 
al., 2014). Despite this, it is definitely bad news for Polish 
Hound breeders because of high risk of producing 
affected offspring in the future.  
 
Conclusion 
 
To our knowledge the case described above is the first 
to report of isolated factor VII deficiency in Polish 
Hound. All dogs intended for breeding should be 
appropriately tested in the future. 
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